Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04889716 · ClinicalTrials.gov registry record · Phase 2
CAR-T Followed by Bispecific Antibodies
A Phase 2 study of Large B-cell Lymphoma and DLBCL - Diffuse Large B Cell Lymphoma, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 2
- Study locations
NCT04889716: Recruiting Phase 2 study of Large B-cell Lymphoma and DLBCL - Diffuse Large B Cell Lymphoma, sponsored by Abramson Cancer Center at Penn Medicine.
NCT04889716 is a Phase 2 study of Large B-cell Lymphoma and DLBCL - Diffuse Large B Cell Lymphoma that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 42 participants, below the 157-participant average among 28 other Large B-cell Lymphoma trials with a reported enrollment target (73% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04889716, a Phase 2 study of Large B-cell Lymphoma and DLBCL - Diffuse Large B Cell Lymphoma, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 2
- Study locations
Study Summary
The research study is being conducted to test the safety and effectiveness of the experimental drug mosunetuzumab (Cohort 1) or obinutuzumab and glofitamab (Cohort 2) when given after CAR (genetically modified) T cells. The study is for patients who have already received a CAR T-cell infusion. Some patients who join the study will receive mosunetuzumab, other patients later in the study may receive a different experimental drug (glofitamab, in combination with obinutuzumab).
Primary Outcome
Complete response will be assessed using Cheson 2014 or Lugano criteria, utilizing simple 5 point score (Deauville score). For this study complete response will be a score of 1 (no uptake), 2 (uptake ≤ mediastinum), or 3 (uptake \>mediastinum but ≤ liver, with no new lesions, and no FDG-uptake in the bone marrow, that is not expected (i.e. due to growth factors or therapy
Conditions Studied
Interventions
- DRUG mosunetuzumab
- DRUG glofitamab
- DRUG obinutuzumab
Study Locations (2)
Nebraska
- University of Nebraska Medical Center - Omaha
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2021-11-05 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 2 |
What NCT04889716 shows while recruiting
NCT04889716 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 157-participant average among 28 other Large B-cell Lymphoma trials with a reported enrollment target (73% lower).
The record links to 2 conditions, with Large B-cell Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which mosunetuzumab is the first listed.
NCT04889716 reports a single indexed study location in Nebraska, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04889716 about?
NCT04889716 is a clinical study titled "CAR-T Followed by Bispecific Antibodies". The research study is being conducted to test the safety and effectiveness of the experimental drug mosunetuzumab (Cohort 1) or obinutuzumab and glofitamab (Cohort 2) when given after CAR (genetically modified) T cells. The study is for patients who have already received a CAR T-cell infusion. Some ...
What is the current status of trial NCT04889716?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2021-11-05. Estimated completion is 2028-12-31.
What conditions does trial NCT04889716 study?
This clinical trial studies the following conditions: Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma.
What interventions are being tested in trial NCT04889716?
The interventions under investigation include: mosunetuzumab (DRUG), glofitamab (DRUG), obinutuzumab (DRUG).
Who is sponsoring clinical trial NCT04889716?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04889716 being conducted?
This trial has 2 study locations across Nebraska, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Large B-cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04889716's enrollment target sits among peer trials
42 13th of 28 higher than 16 of 28 other Large B-cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Large B-cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
RECRUITING · Phase 2
-
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
RECRUITING · Phase 2
-
Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
RECRUITING · Phase 2
-
Emapalumab Prevention of CAR-T Cell Associated Toxicities
RECRUITING · Phase 2
-
Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI